^
Association details:
| Biomarker: | NCOA4-RET fusion |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma
Published date:
08/11/2023
Excerpt:
We present a 13-year-old female with metastatic PTC, clinically resistant to radioactive iodine, and found to harbor a NCOA4-RET fusion. She responded to selpercatinib treatment with the elimination of supplemental oxygen need, marked reduction in pulmonary nodules and mediastinal lymphadenopathy, and biomarker decline. The response was maintained...
DOI:
10.1097/MPH.0000000000002743
